GlassScriptPhysician profile
John Kennison Hudson
NPI 1700863438
$3,072.29
in general payments reported to CMS, 2019-2025
42 companies · $473 in 2025
The $473 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $326 · 2021: $433 · 2022: $400 · 2023: $539 · 2024: $374 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316 · Education: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.45 |
| Education | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $564.41 | 2019-2025 | |
| Janssen Biotech, INC. | $343.73 | 2019-2021 | |
| Pfizer INC. | $204.63 | 2022-2025 | |
| Siemens Medical Solutions USA, INC. | $163.26 | 2023-2024 | Truebeam, Aria Radiation Therapy Management Software |
| Daiichi Sankyo INC. | $160.90 | 2024-2025 | Enhertu, Vanflyta |
| Genzyme Corporation | $160.28 | 2020-2022 | |
| Array Biopharma INC | $120.53 | 2023-2025 | Braftovi, Mektovi, Tukysa |
| US Oncology Corporate, INC. | $109.00 | 2023 | |
| Incyte Corporation | $94.18 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.50 | 2019 | |
| Gilead Sciences, INC. | $85.37 | 2021-2023 | Trodelvy |
| Merck Sharp & Dohme LLC | $79.93 | 2019-2022 | |
| Genentech USA, INC. | $75.35 | 2019-2022 | |
| Stemline Therapeutics INC. | $73.51 | 2023-2025 | Orserdu |
| Kite Pharma, INC. | $67.82 | 2024-2025 | Yescarta |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.